Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star Alloeocomatella polycladia

Marine Drugs

Volumn 10, Issue 4, 2012, Pages 744-761

  Yamashita, Atsuya ^a   Salam, Kazi Abdus ^b   Furuta, Atsushi ^c,d   Matsuda, Yasuyoshi ^c,d   Fujita, Osamu ^c,d   Tani, Hidenori ^b   Fujita, Yoshihisa ^e,f   Fujimoto, Yuusuke ^a   Ikeda, Masanori ^g   Kato, Nobuyuki ^g   Sakamoto, Naoya ^h   Maekawa, Shinya ^a   Enomoto, Nobuyuki ^a   Nakakoshi, Masamichi ⁱ   Tsubuki, Masayoshi ⁱ   Sekiguchi, Yuji ^c   Tsuneda, Satoshi ^d   Akimitsu, Nobuyoshi ^b   Noda, Naohiro ^c   Tanaka, Junichi ^e   Moriishi, Kohji ^a   more..

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d WASEDA UNIVERSITY   (Japan)

^e UNIVERSITY OF THE RYUKYUS   (Japan)

^f Marine Learning Center   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

ⁱ HOSHI UNIVERSITY   (Japan)

Author keywords

Alloeocomatella polycladia; Hepatitis C virus; Marine organism; NS3 helicase

Indexed keywords

ACANTHELLA EXTRACT; AGELAS EXTRACT; ALLOEOCOMATELLA POLYCLADIA EXTRACT; ANTIVIRUS AGENT; CENOMETRA BELLA EXTRACT; COLOBOMETRA PERSPINOSA EXTRACT; COMANTHUS PARVICIRRUS EXTRACT; COMASTER NOBILIS EXTRACT; COMASTER SCHLEGELII EXTRACT; DYSIDEA ARENARIA EXTRACT; DYSIDEA HERBACEA EXTRACT; ECHINOCLATHRIA EXTRACT; FASCIOSPONGIA RIMOSA EXTRACT; HYRTIOS EXTRACT; ISIS HIPPURIS EXTRACT; LAMPROMETRA PALMATA EXTRACT; LEUCETTA EXTRACT; LUFFARIELLA EXTRACT; LYNGBYA EXTRACT; NATURAL PRODUCT; NONSTRUCTURAL PROTEIN 3; OK 99 12; OK 99 13; OK 99 15; OK 99 17; OK 99 18; OK 99 2; OK 99 20; OK 99 21; OK 99 23; OK 99 3; OK 99 37; OK 99 4; OK 99 5; OK 99 9; OXYCOMANTHUS BENETTI EXTRACT; PETROSIA EXTRACT; PHYLLOSPONGIA EXTRACT; PLAKORTIS EXTRACT; PSEUDOCERATINA PURPUREA EXTRACT; SG 1 12 2; SG 1 14 2; SG 1 15 2; SG 1 16 2; SG 1 19 2; SG 1 23 1; SG 1 24 1; SG 1 26 2; SG 1 28 2; SG 1 30 1; SG 3 25; SG 3 26; SG 3 28; STRONGYLOPHORA EXTRACT; THEONELLA CONICA EXTRACT; THEONELLA CUPOLA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOEOCOMATELLA POLYCLADIA; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ECHINODERM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; GENOTYPE; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; NONHUMAN; PROTEIN TARGETING; REPLICON; SPONGE (PORIFERA); VIRUS REPLICATION; VIRUS STRAIN;

ANTEDON; HEPATITIS C VIRUS;

EID: 84860616119     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md10040744     Document Type: Article

References (41)

1. Baldo, V.; Baldovin, T.; Trivello, R.; Floreani, A. Epidemiology of HCV infection. Curr. Pharm. Des. 2008, 14, 1646-1654. (Pubitemid 351998588)
2. Seeff, L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36, S35-S46. (Pubitemid 35253462)
3. Moriishi, K.; Matsuura, Y. Host factors involved in the replication of hepatitis C virus. Rev. Med. Virol. 2007, 17, 343-354. (Pubitemid 47425871)
4. Tsukiyama-Kohara, K.; Iizuka, N.; Kohara, M.; Nomoto, A. Internal ribosome entry site within hepatitis C virus RNA. J. Virol.1992, 66, 1476-1483.
5. Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993, 67, 3835-3844. (Pubitemid 23180705)
6. Kim, D.W.; Gwack, Y.; Han, J.H.; Choe, J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res. Commun. 1995, 215, 160-166.
7. Failla, C.; Tomei, L.; de Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 1994, 68, 3753-3760.
8. Belon, C.A.; Frick, D.N. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol. 2009, 4, 277-293.
9. Frick, D.N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr. Issues Mol. Biol. 2007, 9, 1-20. (Pubitemid 46139067)
10. Kwong, A.D.; Rao, B.G.; Jeang, K.T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 2005, 4, 845-853.
11. Manns, M.P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55, 1350-1359. (Pubitemid 44277369)
12. McHutchison, J.G.; Everson, G.T.; Gordon, S.C.; Jacobson, I.M.; Sulkowski, M.; Kauffman, R.; McNair, L.; Alam, J.; Muir, A.J.; Team, P.S. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360, 1827-1838.
13. Zeuzem, S.; Hultcrantz, R.; Bourliere, M.; Goeser, T.; Marcellin, P.; Sanchez-Tapias, J.; Sarrazin, C.; Harvey, J.; Brass, C.; Albrecht, J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 2004, 40, 993-999. (Pubitemid 38670134)
14. Asselah, T.; Marcellin, P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011, 31 (Suppl. 1), 68-77.
15. Jazwinski, A.B.; Muir, A.J. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol. Hepatol. (NY) 2011, 7, 154-162.
16. Lange, C.M.; Sarrazin, C.; Zeuzem, S. Review article: specifically targeted anti-viral therapy for hepatitis C - A new era in therapy. Aliment. Pharmacol. Ther. 2010, 32, 14-28.
17. Hofmann, W.P.; Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 257-264.
18. Kwong, A.D.; Kauffman, R.S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 2011, 29, 993-1003.
19. Kieffer, T.L.; Kwong, A.D.; Picchio, G.R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 2010, 65, 202-212.
20. Thompson, A.J.; McHutchison, J.G. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J. Viral. Hepat. 2009, 16, 377-387.
21. Belon, C.A.; High, Y.D.; Lin, T.I.; Pauwels, F.; Frick, D.N. Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. Biochemistry 2010, 49, 1822-1832.
22. Maga, G.; Gemma, S.; Fattorusso, C.; Locatelli, G.A.; Butini, S.; Persico, M.; Kukreja, G.; Romano, M.P.; Chiasserini, L.; Savini, L.; et al. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry 2005, 44, 9637-9644.
23. Chin, Y.W.; Balunas, M.J.; Chai, H.B.; Kinghorn, A.D. Drug discovery from natural sources. AAPS J. 2006, 8, E239-E253.
24. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4, 206-220. (Pubitemid 40372555)
25. Li, J.W.; Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? Science 2009, 325, 161-165.
26. Ahmed-Belkacem, A.; Ahnou, N.; Barbotte, L.; Wychowski, C.; Pallier, C.; Brillet, R.; Pohl, R.T.; Pawlotsky, J.M. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010, 138, 1112-1122.
27. Wagoner, J.; Negash, A.; Kane, O.J.; Martinez, L.E.; Nahmias, Y.; Bourne, N.; Owen, D.M.; Grove, J.; Brimacombe, C.; McKeating, J.A.; et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51, 1912-1921.
28. Ciesek, S.; von Hahn, T.; Colpitts, C.C.; Schang, L.M.; Friesland, M.; Steinmann, J.; Manns, M.P.; Ott, M.; Wedemeyer, H.; Meuleman, P.; et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 2011, 54, 1947-1955.
29. Takeshita, M.; Ishida, Y.; Akamatsu, E.; Ohmori, Y.; Sudoh, M.; Uto, H.; Tsubouchi, H.; Kataoka, H. Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J. Biol. Chem. 2009, 284, 21165-21176.
30. Donia, M.; Hamann, M.T. Marine natural products and their potential applications as anti-infective agents. Lancet Infect. Dis. 2003, 3, 338-348. (Pubitemid 36718012)
31. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. Nat. Rev. Drug Discov. 2009, 8, 69-85.
32. Mayer, A.M.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 2010, 31, 255-265.
33. Yokota, T.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Miyagishi, M.; Maekawa, S.; Yi, L.; Kurosaki, M.; Taira, K.; Watanabe, M.; et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003, 4, 602-608.
34. Frese, M.; Barth, K.; Kaul, A.; Lohmann, V.; Schwarzle, V.; Bartenschlager, R. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J. Virol. 2003, 84, 1253-1259. (Pubitemid 36592618)
35. Ikeda, M.; Abe, K.; Dansako, H.; Nakamura, T.; Naka, K.; Kato, N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem. Biophys. Res. Commun. 2005, 329, 1350-1359. (Pubitemid 40568718)
36. Blight, K.J.; Kolykhalov, A.A.; Rice, C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290, 1972-1974.
37. Guo, J.T.; Bichko, V.V.; Seeger, C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol.2001, 75, 8516-8523. (Pubitemid 32768956)
38. Tani, H.; Akimitsu, N.; Fujita, O.; Matsuda, Y.; Miyata, R.; Tsuneda, S.; Igarashi, M.; Sekiguchi, Y.; Noda, N. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem. Biophys. Res. Commun. 2009, 379, 1054-1059.
39. Gallinari, P.; Brennan, D.; Nardi, C.; Brunetti, M.; Tomei, L.; Steinkuhler, C.; De Francesco, R. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J. Virol. 1998, 72, 6758-6769. (Pubitemid 28323995)
40. Huang, Y.; Liu, Z.R. The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase. J. Biol. Chem. 2002, 277, 12810-12815.
41. Jin, H.; Yamashita, A.; Maekawa, S.; Yang, P.; He, L.; Takayanagi, S.; Wakita, T.; Sakamoto, N.; Enomoto, N.; Ito, M. Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication in vitro. Hepatol. Res. 2008, 38, 909-918.